RXi Pharmaceuticals Corporation (RXII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.19+0.01 (+0.85%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.18
Bid1.10 x 700
Ask1.49 x 14000
Day's Range1.16 - 1.29
52wk Range0.94 - 4.60
1y Target EstN/A
Market Cap7.81M
P/E Ratio (ttm)-0.81
Avg Vol (3m)39,300
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire10 days ago

    RXi Pharmaceuticals Plans to Conduct Securities Offering

    MARLBOROUGH, Mass., Oct. 12, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) announced today that it plans to conduct a securities offering in the near future. RXi plans to use the net proceeds from the offering to enable the smooth integration of MirImmune Inc. into RXi in the event that RXi exercises its option to acquire MirImmune Inc. and the timely development of RXi's current pipeline, as well as sd-rxRNA in cell therapy. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

  • PR Newswire10 days ago

    RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.

    MirImmune was co-founded by Tim Barberich, founder and former Chairman and CEO of Sepracor, Inc. In early 2015, RXi and MirImmune entered into an exclusive license agreement to RXi's novel and proprietary sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies.  MirImmune's progress in cell therapy using RXi's RNAi technology during the past 18 months forms a strong foundation for therapeutic development in the immuno-oncology space. If RXi exercises its option to acquire MirImmune, the acquisition would enable RXi to expand its pipeline and enter into the rapidly expanding field of immuno-oncology using the unique competitive advantages of sd-rxRNA technology.

  • PR Newswire11 days ago

    RXi Pharmaceuticals to Present at the 15th Annual BIO Investor Forum

    MARLBOROUGH, Mass., Oct. 11, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...